BioMed Realty’s proposed 585 Third Street, an ambitious 16-story lab complex with 40,000 SF of public, theater, and cultural space in Cambridge’s Kendall Square, received unanimous approval from city officials late last year amidst widespread community support. What does this unusual consensus among residents, developers, and policymakers signal for the future of life sciences development?

Comprised of individuals working closely on the design, development, and approval of 585 Third Street, our panel will examine how the project inspired excitement in development-skeptical Cambridge and what the CRE industry can do to mirror its success. Learn how the proposal broke with traditional models for life sciences buildings in terms of architecture, public benefits, stakeholder engagement, and more. Panelists will share how an early focus on inclusivity in the outreach process led to wider support among underrepresented groups and communities of color. Finally, we will explore what this development means for the long-term outlook of innovation clusters not only in Greater Boston, but nationally.

Kendall Square’s success as a biotech hub has spawned many imitators. As projects like 585 Third Street come online, developers, tenants, and visitors will increasingly expect these innovation hubs to offer amenities, artistic offerings, and retail befitting more traditionally livable neighborhoods. 585 Third Street is a glimpse into the future of the new model for this critical sector of commercial real estate.

Speakers:

Moderator: Lisa Serafin Principal Redgate	Iram Farooq Asst.City Manager for Community Development City of Cambridge

Kishore Varanasi Principal & Director of Urban Design CBT Architects	Sal Zinno Vice President of Development BioMed Realty